News

The latest updates on our research projects and fundraising achievements.

Duchenne Care UK podcast series launched

On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series. The series is based on the Duchenne Care UK Patient and Family Guides and break down information into accessible, short episodes …

read more
Duchenne Care UK strives for best care for all at national meeting

Duchenne Care UK strives for best care for all at national meeting

At the third national meeting for Duchenne Care UK, more than 80 healthcare professionals and patient representatives convened to review the latest developments in care standards, and attend workshops to discuss best practice for the next phase of this groundbreaking national programme …

read more

New Duchenne treatment approved for use in Scotland

Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk. It is currently under review by the UK’s National Institute for Health and Care Excellence (NICE) as to whether it will be approved for use in NHS England …

read more

DMD Care UK cardiac guideline recognised by NICE

NICE logoOn World Duchenne Awareness Day 2025, the Duchenne Research Fund is delighted to share that NICE has recognised the cardiac care guidelines that were created and published by the DMD Care UK programme that we fund …

read more

DMD Care UK publishes annual meeting report

DMD Care UK has published a report following its national meeting earlier this year, sharing insights into the success of its workshops and knowledge sharing. More than 80 clinical professionals attended in person, and there were more than 170 dial-ins …

read more

Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns …

read more

NICE approves DRF-funded treatment for Duchenne

Sheli Rodney, Emily Reuben, Prof Katie Bushby, Prof Michela Guglieri, Alex Johnson, Eric HoffmanThe National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on the NHS to treat Duchenne muscular dystrophy. Vamorolone, also known by the brand name Agamree, will be available to treat people with Duchenne aged 4 and older. The Duchenne Research Fund has helped nurture the development of vamorolone for ten years in a ground-breaking example of venture philanthropy …

read more

Solid expands gene therapy trial

We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003.

read more

Solid begins dosing next-generation gene therapy


We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US …

read more

FDA expands approval for gene therapy Elevidys

The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over …

read more

DMD Care UK launches new respiratory guidance


We are pleased to share that DMD Care UK’s new respiratory guidance has been endorsed by the British Thoracic Society and published in Thorax, an international peer-reviewed medical journal with a respiratory focus. It is published by the BMJ Group on behalf of the British Thoracic Society …

read more

Vamorolone approved in the UK


The Duchenne Reserach Fund is delighted to share that the MHRA has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is not yet available on the NHS …

read more

Vamorolone approved in the EU


The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older …

read more

Vamorolone approved in the US

The US FDA has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree …

read more

See the smart suit that is changing children’s lives


On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart suit’ aims to help children who are losing upper body function in still continuing to use their arms.

read more

Parents urged to read new cardiac recommendations for Duchenne

DMD Care UK’s new cardiac care recommendations have been published in the BMJ Open Heart journal. All Duchenne parents and caregivers are being urged to read the new guidance and share with their networks, as protecting the heart early is crucial to preventing unnecessary deaths. Leading cardiologists, Duchenne specialists and patients and caregivers came together …

read more

Solid data shows improved motor and lung function

We are pleased to share Solid Biosciences' latest update on the IGNITE DMD gene therapy clinical trial. Data after two years suggests that patients' motor function and lung function are improved compared to the declines that would be expected without treatment. The...

read more
#TeamDRF raise £28,000 in London Marathon

#TeamDRF raise £28,000 in London Marathon

Congratulations to #TeamDRF's Adam, Benji, Charles and Yossi who completed the London Marathon on Sunday 3rd October 2021, raising more than £28,000 for the Duchenne Research Fund. The annual event is the largest marathon in the UK, attracting around 40,000...

read more

Watch the highlights of An Evening with the DRF

Watch the highlights of Gavriel Rosenfeld in conversation with Dr Ronni Cohn at our virtual Evening with the Duchenne Research Fund. More than 500 people watched our virtual event to hear Gavriel talk about living with Duchenne, mental health, juggling school and hospital visits, and more …

read more

DRF funds PPMD neurobehavioural research


We have awarded an £80,000 grant to Parent Project Muscular Dystrophy (PPMD) to support its research into neurobehavioral issues in Duchenne – focusing on key areas such as learning, behaviour, depression and anxiety …

read more

DRF funds Duchenne clinic at Great Ormond Street


We are pleased to share that we have awarded a grant of £35,000 to Great Ormond Street Hospital to establish a dedicated clinic for children who are non-ambulant (no longer able to walk). The grant supports the post of Senior Physiotherapist Nicola Burnett and has enabled more than 80 patients to be seen …

read more

DRF grants £40,000 to DMD Care UK project

We have awarded £40,000 to the newly launched DMD Care UK, partnering with the project’s founders Duchenne UK and Joining Jack. Together our three charities will invest £130,000 in the nationwide initiative that aims to ensure the best care for everyone living with Duchenne in the UK …

read more

Run the London Marathon with DRF


We are pleased to announce that the Duchenne Research Fund has places available for the 2021 Virgin Money London Marathon, which is due to take place on Sunday 3rd October …

read more

Solid announces collaboration with Ultragenyx


Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaborations and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne …

read more

Two-year Vamorolone study completed

ReveraGen logo
Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne…

read more

Gene therapy for Duchenne: latest news

Five years ago we identified gene therapy as a viable treatment for Duchenne. Today we are reflecting on the exciting and inspiring events of the past week in the gene therapy arena which are now bringing hope and cautious optimism to the Duchenne community. We have...

read more

Solid Biosciences clear to resume IGNITE DMD

Message from Solid Biosciences: "We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD, our clinical trial investigating SGT-001 as a potential treatment for Duchenne muscular dystrophy (DMD). SGT-001 is a microdystrophin gene...

read more
DRF funds Newcastle refurbishment

DRF funds Newcastle refurbishment

On Wednesday 27 September 2017, the newly refurbished paediatric area in the Clinical Research Facility at Newcastle Royal Victoria Infirmary was officially opened by Professor Mark Walker and Dr Michela Guglieri.

read more

Solid Biosciences news

Solid Biosciences recently reported that it has raised up to $50 million which will enable the biotech to continue to advance its programs for Duchenne muscular dystrophy, including development of a microdystrophin gene. We are forever grateful to our incredible...

read more

DRF raises £140,000 in Yorkshire Three Peaks challenge


On Sunday 9th July 2017, 43 intrepid hikers from London, Manchester and New York donned their walking boots and waterproofs and braved the challenging Yorkshire Three Peaks: a 40km hike with 1600 metres of ascent in a target time of 12 hours, raising money to support vital Duchenne Research Fund projects …

read more

Vamorolone receives Fast Track designation from FDA

We’re pleased to share news from ReveraGen, the company developing the novel steroid alternative Vamorolone (previously called VBP15), that their drug has received Fast Track designation from the FDA, which will speed up the review of Vamorolone.

read more
DRF marks World Duchenne Awareness Day

DRF marks World Duchenne Awareness Day

On Wednesday 7 September 2016, the Duchenne Research Fund team, together with the charity’s co-founder Kerry Rosenfeld and her son Gavriel, marked World Duchenne Awareness Day.

The theme for 2016 is early diagnosis: focusing on how identifying and communicating early signs of Duchenne muscular dystrophy …

read more

Duchenne patients recruited for steroid replacement study

We are delighted to announce that ReveraGen BioPharma, the company developing a steroid replacement for Duchenne muscular dystrophy, has begun recruiting patients for its Phase 2a open label study. The trial will be recruiting patients who haven’t yet started steroids, between the ages of 4 and 7 …

read more

DRF-funded drug development programme receives further £4.6 million

The Duchenne Research Fund, the Duchenne Children’s Trust and Joining Jack and are delighted with the news from the John Walton Muscular Dystrophy Research Centre that they have received £4.26 million in European funding for a Phase II clinical trial for Vamorolone – also known as VBP15 – an anti-inflammatory drug …

read more
Dog with dystrophin mutation saved from Duchenne

Dog with dystrophin mutation saved from Duchenne

DRF-funded research was published this week in Cell, one of the world’s most prestigious scientific journals, analysing why two golden retrievers showed no severe symptoms of Duchenne muscular dystrophy and unexpectedly lived a normal lifespan despite being born with the genetic mutation that causes Duchenne. It is now thought that the results could open up new avenues for possible treatments …

read more
DRF’s funding of Solid GT leads to $42.5 million investment

DRF’s funding of Solid GT leads to $42.5 million investment

We are thrilled that the money raised through the Duchenne Research Fund’s 2013 dinner and donations since then have enabled us to seed fund the incredible Solid GT project, which has today received industry investment (read the press release below). While gene therapy is an exciting piece of the puzzle for beating Duchenne for all boys, it is now more critical than ever that we continue to raise vital funds to push Duchenne therapies into clinical trial as quickly and safely as possible and to get them to our boys NOW.

read more
Albourne raises £155,000 for DRF

Albourne raises £155,000 for DRF

We are immensely grateful to Albourne Partners and their supporters for raising more than £155,000 for our projects at their incredible performance of ‘The Importance of Being Lewis’ on 7 October. The event was held to honour the memory of Jacques Joubert (1992-2015) who had Duchenne …

read more

Gene therapy breakthrough in muscular dystrophy dogs

The Duchenne Research Fund is incredibly proud of Dr Dongsheng Duan – an important Scientific Advisory Board member of Solid GT, a gene therapy programme pioneered by Solid Biosciences and that we helped to fund. Dr Duan’s latest gene therapy work on muscular dystrophy dogs is set to significantly impact 100% of the Duchenne population.

He also recently received a five-year, $3 million grant from the NIH (National Institutes of Health) …

read more

DRF-funded study shows encouraging results in combating muscle-wasting

Professor Dame Kay Davies (University of Oxford) and her group have recently published encouraging results of a study to test new second-generation compounds to increase the level of utrophin protein as a treatment for boys and men with Duchenne and Becker muscular dystrophies.

Utrophin is a protein that occurs naturally in the body. It is usually only made in large amounts during development in the womb and is only present in small amounts in adults. Utrophin is very similar to dystrophin in its structure and previous research has shown that it can compensate for the lack of dystrophin in animal models of Duchenne muscular dystrophy …

read more

Newcastle Plan aims to boost UK clinical trial capacity for Duchenne

Last month the Duchenne Research Fund participated in the UK National Workshop on Duchenne Muscular Dystrophy Clinical Trial Capacity at Newcastle University, hosted by TREAT-NMD. The landmark meeting brought together 75 representatives from patient organisations, pharmaceutical companies, the National Institute for Health Research and a wide range of clinicians, to discuss the challenges and solutions to increase clinical trial capacity in the UK …

read more

Our mission

We aim to stop Duchenne muscular dystrophy being a death sentence for hundreds of thousands of boys worldwide.

Our impact

We are helping turn the hope of treatments into reality. Critical treatments are in clinical trial thanks to our funds.

Your help

Your generosity has funded millions of pounds worth of ground-breaking research.
And there is still work to do.